Search Results - "KEMPTON, C. L."

US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors by Valentino, L. A., Kempton, C. L., Kruse-Jarres, R., Mathew, P., Meeks, S. L., Reiss, U. M.

“…Introduction The development of anti‐factor VIII (FVIII) antibodies (inhibitors) is the most serious treatment‐related complication in patients with hemophilia…”
Get full text

Bone health in persons with haemophilia by Kempton, C. L., Antoniucci, D. M., Rodriguez-Merchan, E. C.

“…Introduction As the population of patients with haemophilia (PWH) ages, healthcare providers are required to direct greater attention to age‐related…”
Get full text

Physician trust and depression influence adherence to factor replacement: a single‐centre cross‐sectional study by Tran, D. Q., Barry, V., Antun, A., Ribeiro, M., Stein, S., Kempton, C. L.

“…Introduction Poor adherence to factor replacement therapy among patients with haemophilia can lead to joint bleeding and eventual disability. Aim The aim of…”
Get full text

Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates by KEMPTON, C. L., SOUCIE, J. M., ABSHIRE, T. C.

“…Background: Development of an inhibitory antibody to factor VIII is currently the most serious complication of hemophilia A treatment. The rate of inhibitor…”
Get full text

Physical activity and functional abilities in adult males with haemophilia: a cross-sectional survey from a single US haemophilia treatment centre by Baumgardner, J., Elon, L., Antun, A., Stein, S., Ribeiro, M., Slovensky, L., Kempton, C.L.

“…Summary Physical activity and functional ability are important determinants of quality of life and these metrics are affected by both haemophilia and ageing…”
Get full text

Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) by Manco‐Johnson, M. J., Kempton, C. L., Reding, M. T., Lissitchkov, T., Goranov, S., Gercheva, L., Rusen, L., Ghinea, M., Uscatescu, V., Rescia, V., Hong, W.

“…Summary Background The benefits of routine prophylaxis vs. on‐demand treatment with factor VIII products have not been evaluated in controlled clinical trials…”
Get full text

Self‐reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P‐FiQ) study by Witkop, M., Neff, A., Buckner, T. W., Wang, M., Batt, K., Kessler, C. M., Quon, D., Boggio, L., Recht, M., Baumann, K., Gut, R. Z., Cooper, D. L., Kempton, C. L.

“…Introduction Haemophilia is characterized by frequent haemarthrosis, leading to acute/chronic joint pain. Aim To assess self‐reported prevalence, description…”
Get full text

Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? by WHITE, G. C., KEMPTON, C. L., GRIMSLEY, A., NIELSEN, B., ROBERTS, H. R.

“…Advances in molecular immunology over the past two decades permit a better understanding of why antibodies develop to peptide antigens like factor VIII and the…”
Get full text

Effect of late prophylaxis in hemophilia on joint status: a randomized trial by Manco‐Johnson, M. J., Lundin, B., Funk, S., Peterfy, C., Raunig, D., Werk, M., Kempton, C. L., Reding, M. T., Goranov, S., Gercheva, L., Rusen, L., Uscatescu, V., Pierdominici, M., Engelen, S., Pocoski, J., Walker, D., Hong, W.

“…Essentials High‐quality data are lacking on use of prophylaxis in adults with hemophilia and arthropathy. SPINART was a 3‐year randomized clinical trial of…”
Get full text

Impact of pain and functional impairment in US adults with haemophilia: Patient‐reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P‐FiQ) study by Kempton, C. L., Recht, M., Neff, A., Wang, M., Buckner, T. W., Soni, A., Quon, D., Witkop, M., Boggio, L., Gut, R. Z., Cooper, D. L.

“…Introduction Standardized and disease‐specific patient‐reported outcome (PRO) instruments assessing pain, functional impairment and health‐related quality of…”
Get full text

Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network by Abshire, T., Cox‐Gill, J., Kempton, C. L., Leebeek, F. W. G., Carcao, M., Kouides, P., Donfield, S., Berntorp, E.

“…Summary Background Treatment of mucosal bleeding (epistaxis, gastrointestinal bleeding, and menorrhagia) and joint bleeding remains problematic in clinically…”
Get full text

Distributed optimisation and control of graph Laplacian eigenvalues for robust consensus via an adaptive multilayer strategy by Kempton, L. C., Herrmann, G., di Bernardo, M.

“…Summary Functions of eigenvalues of the graph Laplacian matrix L, especially the extremal non‐trivial eigenvalues, the algebraic connectivity λ2 and the…”
Get full text

Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database by Puetz, J., Soucie, J. M., Kempton, C. L., Monahan, P. E.

“…Summary Several risk factors for inhibitors have recently been described for haemophilia A. It has been assumed that similar risk factors are also relevant for…”
Get full text

Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study by Antun, A., Monahan, P. E., Manco‐Johnson, M. J., Callaghan, M. U., Kanin, M., Knoll, C., Carpenter, S. L., Davis, J. A., Guerrera, M. F., Kruse‐Jarres, R., Ragni, M. V., Witmer, C., McCracken, C. E., Kempton, C. L.

“…Summary Background Immune tolerance induction (ITI) in patients with congenital hemophilia A is successful in up to 70%. Although there is growing…”
Get full text

A cross‐sectional study of non‐attendance among patients at a US hemophilia treatment center 2010‐2014 by Barry, V., Steffens, C., Mattis, S., Sidonio, R. F., Tran, D. Q., Kempton, C. L.

“…Introduction Among patients with chronic disease, non‐attendance at scheduled healthcare visits is associated with poor outcomes. The impact of non‐attendance…”
Get full text

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients by Collins, P. W., Quon, D. V. K., Makris, M., Chowdary, P., Kempton, C. L., Apte, S. J., Ramanan, M. V., Hay, C. R. M., Drobic, B., Hua, Y., Babinchak, T. J., Gomperts, E. D.

“…Introduction Trenonacog alfa (IB1001) is a recombinant factor IX (rFIX) manufactured in Chinese hamster ovary (CHO) cells. IB1001 was evaluated in a…”
Get full text

Inhibitors in previously treated patients: a review of the literature by KEMPTON, C. L.

“…Previously treated patients are the first patients to receive novel factor VIII products during clinical investigations under the rationale that a product with…”
Get full text

Bone density in haemophilia: a single institutional cross-sectional study by Kempton, C. L., Antun, A., Antoniucci, D. M., Carpenter, W., Ribeiro, M., Stein, S., Slovensky, L., Elon, L.

“…Summary Haemophilia has been associated with low bone mineral density (BMD). However, prior clinical studies of this population have neither clearly elucidated…”
Get full text

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A by KEMPTON, C. L., ABSHIRE, T. C., DEVERAS, R. A., HOOTS, W. K., GILL, J. C., KESSLER, C. M., KEY, N. S., KONKLE, B. A., KURIAKOSE, P., MACFARLANE, D. E., BERGMAN, G.

“…OBI‐1 is a recombinant B‐domain deleted porcine factor VIII (FVIII). FVIII treatment in those with haemophilia A may be complicated by the development of…”
Get full text

Mitral valve repair in a Jehovah's witness with haemophilia A with high-titre inhibitor by Tran, D. Q., Moss, E., Murphy, D. A., Kempton, C. L.

Get full text